Tag:
Newron
Latest Headlines
Latest Headlines
Newron soars on positive PhIII results, $26M pact for Parkinson's drug
Despite being left at the M&A altar last fall after a key partnership deal collapsed, Newron says it has successfully completed two late-stage studies of its experimental Parkinson's drug.
Merck Serono returns rights to Parkinson's drug to Newron
Merck Serono has decided that the experimental Parkinson's disease drug safinamide won't be as strong a commercial drug as once thought. The company, a unit of Germany's Merck KGaA, has handed back
Biotie snares Newron CNS pipeline in $63M share/CVR deal
Finland's Biotie Therapies has struck a deal to acquire Newron Pharmaceuticals ( $NWRN ) for up to $63 million worth of shares. The tie-up--which includes a significant amount tied up in CVRs--creates
Safinamide shows promising Ph3 results against dyskinesia
Merck Serono and Newron Pharmaceuticals may have a promising new add-on treatment for Parkinson's disease sufferers. According to data from an extension of a previous Phase III trial, the company's
Newron ($NWRN), Merck Parkinson's drug misses goal
Newron ( $NWRN ) and Merck KGaA's safinamide failed to perform in a Phase III study of the drug for the involuntary movements associated with Parkinson's disease. The study was designed to test the
Newron shares crash after neuropathic pain drug flunks trial
Shares of Newron Pharmaceuticals ( SW: NWRN ) took a pummeling this morning after the developer revealed that its neuropathic low back pain drug ralfinamide failed to perform any better than a placebo
Newron opens door to pain pact with trial launch
Switzerland's Newron Pharmaceuticals has launched a mid- to late-stage trial for its lower back pain drug ralfinamide. And analysts note that the trial launch positions Newron to ink a significant
Newron Pharma nails $25M equity line
Newron Pharmaceuticals has lined up new financing to get itself through the current economic crisis. The developer--which has been working on new therapies for pain and CNS diseases--has inked an
Italy's Newron buys U.K.-based developer
Italy's Newron Pharmaceuticals has U.K.-based Hunter-Fleming, a company that's developing therapies for neurodegenerative and inflammatory disorders. Newron gains several clinical-stage compounds,
New tests planned after Parkinson's drug fails trial
Merck KGaA and its development partner, Newron, say that a late-stage study of their experimental therapy for Parkinson's failed to demonstrate any significant effect. But the two developers refuse
